Decreased survival with sotalol in the SWORD trial

Results from the Survival With Oral d-Sotalol (SWORD) trial. The administration of d-sotalol to patients with an ejection fraction ≤40 percent after either recent myocardial infarction (MI) or after symptomatic heart failure with a remote (>42 days) MI was associated with increased mortality compared with placebo (5 versus 3.1 percent). The excess number of deaths was presumed to be primarily due to arrhythmias.